[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xencor Inc (XNCR)

Xencor Inc (XNCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,447,993
  • Shares Outstanding, K 74,142
  • Annual Sales, $ 125,580 K
  • Annual Income, $ -91,920 K
  • EBIT $ -212 M
  • EBITDA $ -205 M
  • 60-Month Beta 0.86
  • Price/Sales 11.79
  • Price/Cash Flow N/A
  • Price/Book 2.87

Options Overview Details

View History
  • Implied Volatility 72.30% (-15.63%)
  • Historical Volatility 73.18%
  • IV Percentile 2%
  • IV Rank 4.95%
  • IV High 440.78% on 09/10/25
  • IV Low 53.12% on 08/18/25
  • Expected Move (DTE 22) 0.77 (3.63%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 16
  • Volume Avg (30-Day) 122
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 1,390
  • Open Int (30-Day) 926
  • Expected Range 20.33 to 21.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.84
  • Number of Estimates 5
  • High Estimate $-0.40
  • Low Estimate $-1.08
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) -104.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.38 +46.73%
on 07/16/26
21.26 -0.75%
on 07/21/26
+5.00 (+31.06%)
since 06/30/26
3-Month
10.38 +103.37%
on 05/19/26
21.26 -0.75%
on 07/21/26
+9.17 (+76.87%)
since 04/30/26
52-Week
6.92 +204.91%
on 08/11/25
21.26 -0.75%
on 07/21/26
+12.37 (+141.70%)
since 07/30/25

Most Recent Stories

More News
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties -- -- Ex-U.S. royalties remain unchanged --

XNCR : 21.15 (+8.29%)
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027...

XNCR : 21.15 (+8.29%)
The Biology Came First.

Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...

CGEM : 17.46 (+1.45%)
IDXX : 556.83 (-2.27%)
IPA : 2.07 (+7.25%)
ARGX : 865.75 (-1.90%)
XNCR : 21.15 (+8.29%)
HYFT : 1.3550 (+4.23%)
Xencor: Q1 Earnings Snapshot

Xencor: Q1 Earnings Snapshot

XNCR : 21.15 (+8.29%)
Xencor Reports First Quarter 2026 Financial Results

-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study...

XNCR : 21.15 (+8.29%)
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

-- Data support potentially best-in-class profile of XmAb942, under evaluation in ongoing global Phase 2b XENITH-UC study on track for 12-week induction results in 2027 -- -- Novel XenLockâ„¢...

XNCR : 21.15 (+8.29%)
Stocks Settle Lower as Iran War Boosts Crude Oil and Bond Yields

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.77%. June E-mini...

MSTR : 96.92 (+3.85%)
SOLV : 86.84 (-1.93%)
MPC : 314.22 (+1.78%)
DG : 127.27 (-1.10%)
INTU : 311.32 (-6.55%)
DDOG : 267.58 (+1.28%)
GLXY : 21.34 (+16.87%)
SLB : 48.89 (-0.14%)
XNCR : 21.15 (+8.29%)
$IUXX : 28,031.11 (+3.08%)
COIN : 163.35 (+2.04%)
FICO : 1,140.00 (-16.97%)
Stocks Fall as Iran War Drags On

The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.50%. June E-mini S&P futures (ESM26...

MSTR : 96.92 (+3.85%)
APO : 120.58 (+0.68%)
ARES : 124.31 (-0.23%)
MPC : 314.22 (+1.78%)
DG : 127.27 (-1.10%)
GLXY : 21.34 (+16.87%)
COIN : 163.35 (+2.04%)
FANG : 197.47 (-0.83%)
NTGR : 23.09 (+1.32%)
^BTCUSD : 64,768.35 (+2.13%)
SPY : 739.90 (+1.43%)
ADSK : 234.29 (-4.47%)
Stocks Pressured as Crude Oil Prices and Bond Yields Climb

The S&P 500 Index ($SPX ) (SPY ) today is down -0.80%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.83%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.98%. June E-mini S&P futures...

APO : 120.58 (+0.68%)
BLK : 1,103.98 (+2.30%)
SOLV : 86.84 (-1.93%)
ARES : 124.31 (-0.23%)
DG : 127.27 (-1.10%)
INTU : 311.32 (-6.55%)
DDOG : 267.58 (+1.28%)
XNCR : 21.15 (+8.29%)
$IUXX : 28,031.11 (+3.08%)
FICO : 1,140.00 (-16.97%)
ZNU26 : 108-185 (-0.19%)
SFD : 26.38 (-3.51%)
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals,...

XNCR : 21.15 (+8.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

3rd Resistance Point 20.95
2nd Resistance Point 20.54
1st Resistance Point 20.03
Last Price 21.15
1st Support Level 19.11
2nd Support Level 18.70
3rd Support Level 18.19

See More

52-Week High 21.26
Last Price 21.15
Fibonacci 61.8% 15.78
Fibonacci 50% 14.09
Fibonacci 38.2% 12.40
52-Week Low 6.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.